FDA Class III Medical Devices: PMA Requirements, Clinical Evidence, and the Path to Approval

What Makes a Device Class III?

Class III is the highest-risk classification assigned by the FDA to medical devices marketed in the United States. A device is classified as Class III when it meets one or more of the following criteria defined in Section 513(a)(1)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act):

• It supports or sustains human life
• It is of substantial importance in preventing impairment of human health
• It presents a potential unreasonable risk of illness or injury
• General controls and special controls are insufficient to provide reasonable assurance of its safety and effectiveness

The classification system was established by the Medical Device Amendments of 1976, which divided all medical devices into three risk-based categories — Class I (lowest risk, general controls), Class II (moderate risk, general controls plus special controls), and Class III (highest risk, general controls plus premarket approval). This framework is codified in Sections 513 through 515 of the FD&C Act and implemented through 21 CFR Parts 860 through 892.

Only about 10% of all medical device types regulated by the FDA fall into Class III. But these are among the most consequential devices in medicine — the ones implanted in patients' chests, the ones keeping patients alive during surgery, and the ones whose failure can mean death or permanent disability.

Key distinction: Class I and II devices are "cleared" by the FDA through 510(k) or exemption. Class III devices are "approved" through the Premarket Approval (PMA) process. This is not a semantic difference — it reflects a fundamentally higher evidentiary standard. PMA requires the manufacturer to demonstrate, through valid scientific evidence (usually including clinical trials), that the device is safe and effective for its intended use. A 510(k) only requires a showing of substantial equivalence to a predicate device.

The Two Routes Into Class III

A device ends up classified as Class III through one of two mechanisms:

Route 1 — Classification by regulation. The FDA has classified specific device types as Class III through regulations published in 21 CFR Parts 862-892. Each classified device type has a product code, a regulation number, and a specified submission type (PMA, 510(k), or exempt). If your device matches an existing Class III product code, your path is determined. Examples include replacement heart valves (21 CFR 870.3925), silicone breast implants (21 CFR 878.3530), and cochlear implants (21 CFR 874.3400).

Route 2 — Default classification under Section 513(f). If your device is truly novel — no existing product code describes it — the device is automatically classified as Class III by default. This is the "automatic Class III" provision. The rationale is conservative: if the FDA has not evaluated the device type and cannot determine what controls are needed, the highest level of control applies. Manufacturers of novel devices can seek reclassification into Class I or II through the De Novo pathway (Section 513(f)(2)), but only if they can demonstrate that general controls (Class I) or general plus special controls (Class II) are sufficient to provide reasonable assurance of safety and effectiveness.

This default-to-Class-III rule is why understanding the classification system is not optional. A startup developing a novel technology may discover that their innovative but relatively low-risk device has been placed in Class III simply because no existing classification covers it. Without a De Novo petition, they would face the full PMA burden — $579,272 in user fees, clinical trial requirements, and a multi-year timeline — even if the risk profile of the device might warrant Class II.

The Legal Foundation: Sections 513, 514, and 515 of the FD&C Act

Understanding Class III devices requires familiarity with the three statutory sections that govern the classification system:

Section 513 — Classification of Devices

Section 513 establishes the three-tier classification framework and defines the criteria for each class. It also authorizes the FDA to classify new devices and reclassify existing ones. Key provisions include:

• 513(a): Defines the three classes and their regulatory controls
• 513(b): Establishes classification panels (advisory committees of outside experts) to make recommendations to the FDA
• 513(e): Authorizes reclassification of devices based on new information
• 513(f): Addresses classification of novel devices — any new device with no existing classification defaults to Class III unless the manufacturer submits a De Novo request to classify it into Class I or II
• 513(g): Allows manufacturers to request a formal determination of their device's classification

Section 514 — Special Controls for Class II

Section 514 deals with the special controls that apply to Class II devices. While not directly governing Class III, it matters because the insufficiency of special controls is what separates Class III from Class II. If the FDA determines that special controls cannot adequately mitigate the risks of a device type, that device type remains or becomes Class III.

Section 515 — Premarket Approval

Section 515 is the core statutory authority for PMA. It defines:

• The requirement for PMA applications for Class III devices
• The contents required in a PMA application
• The FDA review process, including advisory panel review
• Post-approval requirements, including annual reporting and PMA supplements
• The process for calling for PMAs from manufacturers of pre-amendment Class III devices (Section 515(b))

Class III Device Examples by Medical Specialty

Class III devices span virtually every area of medicine. The following table provides examples organized by the FDA's medical specialty panels (21 CFR Parts 862-892):

Medical Specialty	Class III Device Examples	Product Codes
Cardiovascular (Part 870)	Replacement heart valves, coronary stents (drug-eluting), implantable pacemakers, implantable cardioverter-defibrillators (ICDs), ventricular assist devices (VADs), total artificial hearts, catheter balloon repair kits	DTE, NIQ, LWS, LLZ, DSQ
Orthopedic (Part 888)	Total hip replacement prostheses (metal-on-metal), intervertebral body fusion devices (certain types), certain bone morphogenetic proteins for spinal fusion	MQP, MAX
Neurological (Part 882)	Implantable cerebellar/cortical stimulators, deep brain stimulators, responsive neurostimulators (RNS) for epilepsy, implanted spinal cord stimulators	GXM, PFC
Ophthalmic (Part 886)	Intraocular lenses (IOLs), implantable miniature telescopes for macular degeneration, phakic IOLs for refractive correction	HQD, HQL
General & Plastic Surgery (Part 878)	Silicone gel-filled breast implants, saline-filled breast implants, absorbable adhesion barriers	OYE, MQM
Ear, Nose & Throat (Part 874)	Cochlear implants, auditory brainstem implants	GYG, MAG
Obstetrical/Gynecological (Part 884)	Preterm labor uterine monitors (certain types), PMA-required contraceptive devices	HEF
Gastroenterology/Urology (Part 876)	Penile inflatable implants, implantable electrical urinary incontinence systems, gastric neurostimulators	FAJ, OBO
Anesthesiology (Part 868)	High-frequency ventilators, extracorporeal membrane oxygenators (ECMO)	BTT, KFP
Immunology/Microbiology (Part 866)	HIV blood donor screening tests, nucleic acid-based tests for high-risk infectious disease screening	QKA, PNH
Radiology (Part 892)	Full-field digital mammography systems (certain types), PET scanners used for specific high-risk diagnostic claims	JAK, MNJ

Practical tip: Do not guess your device's classification. Search the FDA Product Classification Database at accessdata.fda.gov using your device description. The database returns the product code, device class, regulation number, and the required submission type. If you cannot find a matching classification, your device may be novel — in which case it defaults to Class III under Section 513(f) unless you pursue a De Novo classification request.

Notable Class III Device Categories in Depth

Some Class III device categories deserve particular attention because of their regulatory complexity, prevalence, or the lessons they offer to other manufacturers:

Implantable cardiac devices — Pacemakers, ICDs, cardiac resynchronization therapy (CRT) devices, and left ventricular assist devices (LVADs) represent the largest and most well-established category of Class III devices. These devices have decades of PMA history, extensive post-approval study data, and well-defined FDA expectations for clinical evidence. The FDA's cardiovascular device division has specific guidance documents for most cardiac device types, and manufacturers benefit from clear precedents — but must also meet increasingly demanding requirements for long-term follow-up data (often 5+ years) and real-world evidence from post-approval registries.

Breast implants — Silicone gel-filled breast implants have one of the most complex regulatory histories of any Class III device. They were originally marketed before 1976 (pre-amendment), were the subject of a PMA call in 1991, were effectively removed from the cosmetic market from 1992 to 2006 while safety data was collected, and were ultimately re-approved with significant post-approval study requirements. Current PMA holders for breast implants are required to conduct 10-year post-approval studies with thousands of enrolled patients — among the largest and longest post-approval study requirements for any device type.

Cochlear implants — These devices illustrate how a Class III device can transform an entire field of medicine. First approved via PMA in the 1980s, cochlear implants have gone through numerous PMA supplements expanding indications, improving technology, and extending candidacy criteria. The iterative PMA supplement process for cochlear implants demonstrates how the PMA lifecycle works in practice — each generation of technology builds on the approved device through supplements rather than entirely new PMA applications.

Artificial hearts and ventricular assist devices — These represent the most complex end of the Class III spectrum. Total artificial hearts and destination therapy LVADs sustain life entirely, and their PMA applications involve some of the most extensive clinical trials in the device industry — often with hundreds of patients followed for years, bridge-to-transplant and destination therapy protocols, and complex endpoint hierarchies. The FDA has convened advisory panels for many of these devices, and the public panel discussions provide valuable insight into how the agency evaluates benefit-risk for the highest-risk device categories.

Diagnostic tests for high-risk conditions — Not all Class III devices are implants or therapeutic devices. Certain in vitro diagnostic (IVD) tests are classified as Class III because of the clinical consequences of a false result. HIV blood donor screening tests, for example, are Class III because a false negative could result in transmission of HIV through the blood supply. These devices follow the PMA pathway but with an emphasis on analytical performance (sensitivity, specificity, limit of detection) rather than the surgical outcome data typical of implantable device PMAs.

How to Confirm Your Device Is Class III

If you are unsure whether your device is Class III, use this systematic process:

Step 1 — Search the FDA Product Classification Database. Go to accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm. Enter a generic description of your device (not a brand name). Review the results for a matching device description, and note the product code, device class, and submission type.

Step 2 — Read the classification regulation. Click through to the 21 CFR regulation number associated with the product code. The regulation text describes the device type, its intended use, and its classification. For Class III devices, the regulation will specify PMA as the required submission type.

Step 3 — Check for reclassification orders. Some devices that were historically Class III have been reclassified to Class II through the 515 Program Initiative or other reclassification actions. Check the FDA's reclassification page and the Federal Register for any orders affecting your device type.

Step 4 — If no match exists, consider a 513(g) request. If you cannot find your device in the classification database and are unsure about its classification, you can submit a formal 513(g) request to the FDA. The FDA will review your device description and intended use and provide a written determination of the appropriate classification. The response typically takes 60 days.

Step 5 — Evaluate De Novo eligibility. If your device defaults to Class III under Section 513(f) because no existing classification exists, evaluate whether the device's risk profile might support De Novo classification into Class I or II. This analysis should consider the nature of the risks, whether they can be mitigated through general controls and special controls, and whether there is sufficient existing data to support the safety and effectiveness of the device type.

The Premarket Approval (PMA) Pathway

What Is a PMA?

The Premarket Approval Application (PMA) is the most rigorous type of premarket submission required by the FDA. It is the pathway to market for most Class III medical devices. The PMA process is defined in 21 CFR Part 814, and the FDA's standard of review is "reasonable assurance of safety and effectiveness" — a standard that requires valid scientific evidence, typically including data from well-controlled clinical investigations.

Unlike the 510(k) pathway, which requires only a demonstration of substantial equivalence to a predicate device, the PMA demands affirmative evidence that the device works as intended and that its benefits outweigh its risks. There is no predicate device concept in PMA — each device is evaluated on its own merits.

PMA Application Contents (21 CFR 814.20)

A PMA application is a substantial document, often running thousands of pages. The required contents include:

1. Table of contents and administrative information — Applicant identity, device name, device classification, and establishment registration numbers

2. Summary of safety and effectiveness (SSED) — A comprehensive summary of all data supporting the device's safety and effectiveness. The FDA publishes the SSED publicly upon approval, so it should be written for a broad audience

3. Device description — Detailed description of the device, including engineering drawings, photographs, materials specifications, functional components, and principles of operation. For software-driven devices, this includes software architecture, hazard analysis, and verification/validation documentation

4. Reference to performance standards — Identification of all relevant FDA-recognized consensus standards and the extent to which the device conforms to them

5. Non-clinical laboratory studies — Bench testing, biocompatibility testing (per ISO 10993), animal studies, simulated-use testing, shelf-life/stability data, sterilization validation, electromagnetic compatibility, and software verification and validation

6. Clinical investigations — Reports of all clinical studies of the device, including:

   • Investigational device exemption (IDE) number
   • Study protocol and statistical analysis plan
   • Patient demographics and enrollment data
   • Safety data (adverse events, device-related complications)
   • Effectiveness data (primary and secondary endpoints)
   • Analysis of results, including subgroup analyses

7. Manufacturing information — Description of manufacturing methods, facilities, quality control procedures, and packaging/sterilization processes. Must demonstrate compliance with the Quality Management System Regulation (QMSR, formerly 21 CFR Part 820, transitioning to incorporate ISO 13485 by reference as of February 2, 2026)

8. Labeling — Proposed labels, instructions for use, and any required patient labeling or medication guides

9. Environmental assessment or claim for categorical exclusion — Per 21 CFR Part 25

10. Bibliography — All published and unpublished reports relevant to the device

11. Samples — Device samples for FDA evaluation, if requested

12. Financial disclosure statements — FDA Forms 3454 and 3455, certifying or disclosing the financial interests and arrangements of clinical investigators who participated in PMA clinical studies. These forms are required under 21 CFR Part 54 and must be submitted for every clinical investigator involved in any study relied upon in the PMA

13. Cover sheet — FDA Form 3514 (voluntary but recommended), providing administrative summary information for FDA processing

14. User fee payment — Proof of MDUFA user fee payment

The PMA Review Process

The FDA review of a PMA application follows a structured process with defined milestones:

Day 0 — Submission received. The FDA day clock begins.

Days 1-15 — Acceptance review. FDA performs a Refuse to Accept (RTA) screening per the RTA checklist. This is a threshold check — is the application administratively complete? Are all required sections present? If the application fails RTA, it is returned to the applicant and the day clock stops.

Days 15-45 — Filing review. If accepted, FDA conducts a more substantive filing review to determine whether the application contains sufficient information to permit a substantive review. If filed, FDA sends a Filing Letter.

Days 45-180 — Substantive review. FDA scientists and engineers review the application in depth. During this period:

• FDA may send Major Deficiency Letters identifying significant issues that must be resolved. The day clock typically stops while the applicant responds.
• Interactive review is now the norm — FDA and the applicant communicate through email, teleconferences, and in-person meetings to resolve questions iteratively rather than through formal deficiency rounds.
• Most PMA reviews involve two to three rounds of major deficiency questions before the FDA locks its decision package.

Day 100 — Mid-review meeting. The applicant may request a meeting with the FDA within 100 days of the PMA filing. Before this meeting, the FDA will inform the applicant of any deficiencies identified to date. The Day-100 meeting is a critical checkpoint — it provides a structured opportunity for open dialogue between the FDA review team and the sponsor, allowing both parties to address substantive questions, clarify data interpretation issues, and discuss any significant concerns that have emerged during the review. Applicants should prepare for this meeting as rigorously as they would for a Pre-Sub — bring your clinical team, your statistician, and your regulatory lead, because the questions at this stage are technical and consequential.

Advisory panel review (if applicable). For certain device types — particularly novel technologies, first-of-a-kind devices, or devices with significant public health implications — the FDA convenes an advisory panel of external experts. The panel holds a public meeting, reviews the PMA application, and votes on whether the evidence supports a finding of safety and effectiveness. The panel then submits a final report to the FDA with its recommendations. The panel's recommendation is advisory and not binding, but the FDA frequently follows panel recommendations. When an advisory panel is convened, the FDA's target total time to decision extends from 180 FDA-days to 320 FDA-days.

Day 180 — FDA action. The FD&C Act requires the FDA to act on a PMA within 180 days. In practice, clock stops for deficiency responses mean the total calendar time is much longer — typically 12 to 18 months from original submission to final decision, and sometimes longer for complex devices. Under MDUFA V performance goals (FY2023-2027), the FDA and industry have agreed to a shared outcome target of 285 total calendar days (including both FDA review time and sponsor response time) for original PMA and Panel-Track Supplement decisions.

FDA can issue one of four action letters:

Action Letter	Meaning
Approval	The device may be marketed in the United States under the conditions of approval
Approvable	Minor issues remain; the PMA can be approved after the applicant addresses specific conditions
Not Approvable	Fundamental deficiencies exist that require substantial new data or redesign
Denial (Withdrawal)	The application is denied; the applicant may request a hearing

Practical tip: A "Not Approvable" letter is not necessarily the end. It describes the application's deficiencies and may identify what would be needed to make it approvable. Many successful PMAs received at least one Not Approvable letter before ultimate approval. However, the required remediation — often additional clinical studies — can add years and millions of dollars to the process.

PMA Approval Statistics and Success Rates

Understanding PMA approval rates helps set realistic expectations. Key statistics include:

• Ultimate approval rate exceeds 90% — Most PMA applications that enter substantive review are eventually approved, but many require multiple review cycles with deficiency responses before reaching a positive decision.
• First-cycle approval rate is approximately 30-40% — Only about one in three PMAs clears on the first review cycle without major deficiencies requiring additional data or redesign. The gap between first-cycle and ultimate approval reflects the iterative nature of PMA review.
• Advisory panel approval rates improved significantly after 2010 — When the FDA restructured its advisory panel process in 2010, the panel approval rate rose from approximately 70% to over 92%. The change involved better pre-panel preparation and more structured panel deliberations.
• Annual volume of original PMA approvals — The FDA typically approves 25 to 40 original PMAs per year (excluding supplements). In 2022, the FDA approved 23 first-time PMAs/HDEs. In 2023, this increased to approximately 31 original PMA approvals — a pace that has generally held steady through 2025.
• PMA supplements far exceed original PMAs — In any given year, the FDA processes hundreds of PMA supplements (for manufacturing changes, labeling updates, and design modifications) in addition to original PMAs. The supplement workload reflects the ongoing post-approval regulatory relationship that PMA approval creates.

These numbers underscore an important point: PMA is a demanding process, but it is not designed to exclude devices from the market. It is designed to ensure that the evidence supporting safety and effectiveness is sufficient before the device reaches patients.

FDA Facility Inspection During PMA Review

An often-overlooked part of the PMA process is the preapproval inspection. Before approving a PMA, the FDA's Office of Regulatory Affairs (ORA) conducts an on-site inspection of the applicant's manufacturing facility. This inspection evaluates:

• Quality Management System (QMS) compliance — The facility must demonstrate compliance with the QMSR (21 CFR Part 820, transitioning to incorporate ISO 13485). Inspectors review your design controls, CAPA system, document control, management review, purchasing controls, production and process controls, and complaint handling procedures.
• Manufacturing capability — The inspector verifies that the facility can actually produce the device as described in the PMA. This includes reviewing process validation data, equipment calibration, environmental controls, and operator training records.
• Design History File (DHF) — The inspector will review the DHF to confirm that design and development activities were conducted in accordance with design control requirements. This includes design inputs, outputs, verification, validation, design reviews, and design transfer.
• Device Master Record (DMR) — The DMR must contain the complete manufacturing specifications, including drawings, component specifications, production processes, quality assurance procedures, and labeling.

If the inspection reveals significant findings (FDA Form 483 observations), the PMA review may be delayed until the manufacturer addresses the issues. In severe cases, inspectional findings can result in a Warning Letter, which effectively blocks PMA approval until resolved.

Practical tip: Schedule an internal mock audit of your facility 3 to 6 months before your anticipated PMA submission date. Use the FDA's Quality System Inspection Technique (QSIT) guide as your framework. Address any gaps before the FDA inspector arrives — inspectional findings during PMA review are far more consequential than findings during a routine surveillance inspection.

The Four PMA Application Methods

The FDA recognizes four distinct methods for submitting a PMA application. Each method is suited to a different stage of device development. Understanding which method to use — and when — is a strategic decision that should be made early.

Method	Best For	Key Characteristic
Traditional PMA	Devices that have completed clinical testing	Complete application submitted at once
Modular PMA	Devices still in clinical studies	Individual modules submitted and reviewed as completed
Product Development Protocol (PDP)	Devices using well-established technology	FDA-approved protocol guides development
Humanitarian Device Exemption (HDE)	Devices for conditions affecting fewer than 8,000 patients/year	Lower evidentiary standard ("probable benefit")

The Traditional PMA — a single, comprehensive application submitted after clinical testing is complete — is the most common method and is what most of this guide describes. The Modular PMA and PDP methods are alternatives designed for specific situations.

Modular PMA

The Modular PMA is an application method designed for manufacturers whose devices have not yet completed clinical testing but who want to begin the FDA review process on completed portions of their application. Instead of waiting until every section is ready and submitting a single package, the manufacturer deconstructs the PMA into discrete modules — such as preclinical data, manufacturing information, and clinical data — and submits each module to the FDA as it is completed.

The FDA reviews each module as it is received. By the time the final module (typically the clinical data) is submitted, the FDA has already reviewed and provided feedback on the earlier modules, which can significantly reduce the total time from final submission to approval decision.

When to use Modular PMA:

• Your device is in the early or middle stages of clinical investigation and you have completed significant preclinical work
• Your device design is stable and unlikely to change during the clinical study
• You want to reduce the post-submission review timeline by front-loading FDA review of non-clinical sections

When NOT to use Modular PMA:

• You are close to completing your clinical study and could submit a Traditional PMA soon — the administrative overhead of modular submission may not save time
• Your device design is in flux or likely to change based on clinical study results — changes to already-reviewed modules could require re-review and negate the time savings
• Your preclinical testing program is not yet complete — modules should represent finished work, not preliminary data

To initiate a Modular PMA, the manufacturer submits a "PMA Shell" that establishes the overall structure and identifies the planned modules. Each subsequent module is submitted as a stand-alone package with complete data for that section. The FDA's guidance document "Premarket Approval Application Modular Review" provides detailed instructions on structuring and submitting modular PMAs.

Practical tip: The Modular PMA can be strategically valuable for devices with long clinical trials (3+ years), because it allows preclinical, manufacturing, and quality system modules to be reviewed during the trial rather than after it. However, it requires disciplined planning — the module boundaries must be clearly defined, and each module must stand on its own without requiring cross-reference to unsubmitted sections.

The Product Development Protocol (PDP)

The Product Development Protocol (PDP) is a rarely used alternative to the standard PMA. Defined in 21 CFR Part 814, Subpart F, the PDP allows a manufacturer to work collaboratively with the FDA throughout the device development process rather than submitting a completed PMA at the end.

Under a PDP:

• The manufacturer submits a protocol describing the planned development, testing, and clinical evaluation before conducting the work
• The FDA reviews and approves the protocol, and the manufacturer follows it during development
• Upon completion, the manufacturer submits a "Notice of Completion" rather than a full PMA application
• If the FDA determines that the protocol was followed and the results support safety and effectiveness, the device is declared "completed" (equivalent to PMA approval)

The PDP is theoretically advantageous because it reduces the risk of conducting development work that the FDA later deems insufficient. In practice, however, very few manufacturers use the PDP pathway because:

• It requires early and continuous FDA engagement, which can be time-consuming
• The protocol must be approved before major development work begins, which may not align with how companies actually develop devices
• The FDA's own guidance notes that the PDP is rarely used

The PDP user fee is the same as the PMA fee ($579,272 for FY2026).

Breakthrough Device Designation for Class III Devices

The Breakthrough Device Designation program (formerly the Expedited Access Pathway and Priority Review program) provides certain benefits for devices that meet specific criteria. To qualify, a device must:

1. Provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition, AND
2. Meet at least one of the following:
   • Represents a breakthrough technology
   • No approved or cleared alternatives exist
   • Offers significant advantages over existing approved or cleared alternatives
   • Device availability is in the best interest of patients

For Class III devices with Breakthrough Designation, the FDA provides:

• Priority review of the PMA application
• Interactive and timely communication during the review process
• Involvement of senior FDA management in the review
• Opportunities for data development and review in pre-submission interactions, including exploration of clinical study designs that may be more efficient (e.g., Bayesian adaptive designs, real-world evidence, surrogate endpoints)
• Consideration of post-market data collection as a means to expedite premarket review while ensuring appropriate safety monitoring

Breakthrough Designation does not change the evidentiary standard for PMA — the FDA still requires reasonable assurance of safety and effectiveness. But it can meaningfully accelerate the timeline by ensuring faster, more collaborative FDA review.

To apply for Breakthrough Designation, submit a request to the FDA at any time during development. The FDA responds within 60 days. Include a description of the device, the disease or condition it addresses, evidence of breakthrough characteristics, and why it meets the designation criteria.

Clinical Trial Requirements for PMA

The Investigational Device Exemption (IDE)

Before you can conduct a clinical trial of a Class III medical device in the United States, you must obtain an approved Investigational Device Exemption (IDE) from the FDA. The IDE process is governed by 21 CFR Part 812.

An IDE application includes:

• Study protocol — Objectives, study design, inclusion/exclusion criteria, primary and secondary endpoints, sample size justification, statistical analysis plan
• Investigator agreements — Each clinical site investigator must sign an agreement committing to follow the protocol, applicable regulations, and Institutional Review Board (IRB) requirements
• Device description and manufacturing information — Including evidence that the device can be manufactured consistently
• Prior investigations — Results of all prior bench, animal, and clinical testing
• Risk analysis — Per ISO 14971

The FDA reviews the IDE and may approve it, approve it with conditions, or disapprove it. IDE approval allows the device to be shipped across state lines for investigational purposes and provides exemptions from certain regulatory requirements (such as registration, listing, and 510(k)/PMA requirements) while the study is ongoing.

Significant Risk vs. Non-Significant Risk Devices

The IDE requirements differ depending on whether the device is classified as "significant risk" (SR) or "non-significant risk" (NSR):

• Significant risk devices require full IDE approval from the FDA before the study can begin. All Class III devices undergoing a pivotal clinical trial are significant risk by definition — they sustain life, are implanted, or present potential unreasonable risk.
• Non-significant risk devices require only IRB approval (no FDA IDE submission needed). This category is not typically relevant for Class III PMA devices but may apply to feasibility studies of modified versions of cleared devices.

For significant risk devices, the FDA has 30 calendar days to review the IDE. If the FDA does not respond within 30 days, the IDE is considered approved by default. However, most IDE applications receive comments or conditions from the FDA, and waiting for explicit approval before beginning enrollment is strongly recommended.

Early Feasibility Studies

Before committing to a full pivotal trial, many Class III device manufacturers conduct an Early Feasibility Study (EFS). An EFS is a small-scale clinical study (typically 10-30 patients) designed to:

• Provide initial clinical safety data
• Assess device performance in a real clinical setting
• Inform the design of the pivotal trial (endpoints, patient selection, procedural technique)
• Identify design issues that may need to be addressed before a larger study

The FDA has issued specific guidance on IDE applications for Early Feasibility Studies, recognizing that these studies serve a different purpose than pivotal trials and should be evaluated with more flexibility regarding manufacturing maturity and long-term data requirements.

Pivotal Clinical Studies

The clinical evidence supporting a PMA typically comes from one or more pivotal clinical studies. These are the definitive studies designed to demonstrate that the device is safe and effective for its intended use. Key characteristics of PMA pivotal studies:

• Randomized controlled trials (RCTs) are the gold standard, but the FDA accepts other designs (single-arm studies with performance goals, historically controlled studies, Bayesian adaptive designs) when randomization is not feasible or ethical
• Sample sizes vary enormously depending on the device type, the condition being treated, and the endpoints chosen. A cardiac device may require 500 to 2,000 or more patients; a rare-condition device might use a few dozen
• Follow-up periods must be long enough to demonstrate durability of the treatment effect and capture late-occurring adverse events. For implantable devices, this is often 12 to 24 months minimum, with some studies requiring 5+ years of follow-up
• Multi-site enrollment is typical to ensure generalizability of results
• Good Clinical Practice (GCP) compliance per 21 CFR Parts 50 (informed consent), 54 (financial disclosure), 56 (IRB review), and 812 (IDE requirements)

Pre-Submission (Pre-Sub) Meetings

Before investing in a pivotal trial, manufacturers should use the Pre-Submission (Q-Sub) process to align with FDA on the clinical study design. In a Pre-Sub meeting, the FDA will provide feedback on:

• Whether the proposed endpoints are acceptable
• Whether the study design (RCT, single-arm, adaptive) is appropriate
• Sample size and statistical considerations
• Whether bench and animal data are sufficient to support proceeding to a clinical study
• Labeling and intended use questions

Practical tip: The Pre-Sub is arguably the most valuable tool available to PMA applicants. A well-prepared Pre-Sub can prevent years of wasted effort. Submit detailed questions, not vague requests for guidance. Include your proposed study protocol, statistical analysis plan, and a clear description of the device. The FDA feedback you receive in a Pre-Sub is documented and can be referenced in your PMA application. Under MDUFA V performance commitments (FY2023-2027), the FDA must respond to 95% of written Q-Sub feedback requests within 70 calendar days — so you can plan your development timeline around receiving Pre-Sub feedback within approximately two and a half months of submission.

PMA Supplements: Managing Post-Approval Changes

Once a PMA is approved, any change that affects the safety or effectiveness of the device requires FDA review before implementation. The type of review depends on the significance of the change. PMA supplement requirements are defined in 21 CFR 814.39.

Types of PMA Supplements

Supplement Type	Purpose	FDA Review Goal	User Fee (FY2026)
Panel-Track Supplement	Major changes — new indications for use, significant design changes requiring new clinical data. May go to advisory panel	180 days (same as original PMA)	$289,636 (50% of PMA fee)
180-Day Supplement	Significant changes in components, materials, design, or labeling where existing clinical data can mostly support safety/effectiveness	180 days	$173,782 (30% of PMA fee)
Real-Time Supplement	Minor changes where FDA and the sponsor agree to an interactive, expedited review — often conducted via a joint review meeting	~30 days	$26,067
30-Day Notice	Manufacturing process changes that affect safety/effectiveness but can be adequately described without a full supplement. Manufacturer may distribute 30 days after FDA receipt unless FDA objects	30 days (automatic if no objection)	None
Special PMA Supplement — Changes Being Effected	Certain labeling changes (e.g., adding warnings) that enhance safety. Manufacturer may implement before FDA review is complete	Ongoing	$26,067
135-Day Supplement	When a 30-day notice is found inadequate, FDA converts it to a 135-day supplement requiring more detailed review	135 days	$26,067

PMA Annual Reports (21 CFR 814.84)

Every PMA holder must submit an annual report to the FDA within 60 days of the anniversary of the original approval date. The annual report is not optional — it is a condition of continued approval. Required content includes:

• Updated bibliography of all published and unpublished reports about the device
• Summary of changes made under 30-day notices or that did not require a supplement
• Manufacturing changes not requiring a supplement
• Updated labeling (if changed)
• Distribution data — Number of devices distributed during the reporting period, broken down by model number
• Adverse event summaries — All MDR-reportable events, complaint trends, and any new risk information
• Status of post-approval study commitments and any required post-market studies
• Device failure and replacements data

Practical tip: Do not treat the annual report as a box-checking exercise. FDA reviewers read these reports, and patterns in complaint data or distribution spikes can trigger a request for additional information — or a post-approval study requirement. Write the report with the same care you would apply to the original PMA.

Post-Approval Requirements

PMA approval is not the finish line — it is the beginning of a lifelong regulatory relationship with the FDA. Post-approval obligations for Class III devices are more extensive than for any other device class.

Post-Approval Studies (PAS)

The FDA frequently conditions PMA approval on the manufacturer's commitment to conduct post-approval studies. These are clinical studies designed to evaluate the long-term safety and effectiveness of the device in a broader, real-world patient population. Requirements are specified in the PMA approval order under 21 CFR 814.82.

PAS requirements may include:

• Enrollment of a specified number of patients in a registry or study
• Follow-up for a defined period (often 5 to 10 years for implants)
• Reporting at defined intervals (annual or more frequent)
• Analysis of specific safety endpoints (e.g., device failure rates, revision surgery rates)

Failure to comply with PAS requirements can result in withdrawal of PMA approval.

Medical Device Reporting (MDR)

All manufacturers of Class III devices must comply with the MDR regulation (21 CFR Part 803). This requires reporting to the FDA:

• Deaths — Within 30 calendar days of becoming aware that a device may have caused or contributed to a death
• Serious injuries — Within 30 calendar days
• Malfunctions — Within 30 calendar days if the malfunction would be likely to cause or contribute to a death or serious injury if it were to recur

Device Tracking (21 CFR Part 821)

Certain Class III devices — particularly life-sustaining and life-supporting implants — are subject to mandatory tracking requirements. Manufacturers must maintain records sufficient to track each device from manufacturing through the distribution chain to the patient.

Recalls and Corrections

If a Class III device is found to present a risk to health, the manufacturer may be required to initiate a recall or field correction. Because of the device tracking requirements, manufacturers of Class III devices must be able to identify and contact every patient who received the device.

Recalls are classified by the FDA into three categories based on the severity of the health hazard:

• Class I recall — Reasonable probability that use of or exposure to the device will cause serious adverse health consequences or death. For Class III devices, this is the most critical scenario and requires immediate action.
• Class II recall — Use of or exposure to the device may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote.
• Class III recall — Use of or exposure to the device is not likely to cause adverse health consequences.

For implantable Class III devices, a recall does not necessarily mean the device is physically retrieved from the patient. In many cases, the corrective action involves software updates, labeling changes, revised surgical techniques, or enhanced monitoring recommendations — removal of an implanted device carries its own surgical risks that must be weighed against the identified hazard.

Withdrawal of PMA Approval

The FDA has the authority to withdraw PMA approval under 21 CFR 814.46 if it determines that:

• The device is unsafe or ineffective under the conditions of use prescribed in the labeling
• The applicant has not complied with post-approval requirements (annual reports, post-approval studies, PMA supplements for changes)
• The PMA application contained untrue statements of material fact
• The manufacturing facility is not in compliance with QMSR/GMP requirements

Withdrawal of PMA approval is rare but consequential — the manufacturer must stop marketing the device and may be required to recall devices already in distribution. The FDA must provide the manufacturer with notice and an opportunity for a hearing before withdrawing approval.

Unique Device Identification (UDI) Requirements

Class III devices are subject to the FDA's Unique Device Identification (UDI) system under 21 CFR Part 830. Manufacturers must:

• Assign a UDI to each device (including a device identifier and production identifier)
• Submit device information to the FDA's Global Unique Device Identification Database (GUDID)
• Include the UDI on device labels and packages in both human-readable and machine-readable (AIDC) formats
• For implantable devices, ensure the UDI is on the device itself (direct marking) if technologically feasible

Class III devices were among the first devices required to comply with UDI requirements when the system was phased in. UDI compliance is verified during preapproval inspections and routine surveillance inspections.

The QMSR Transition and Its Impact on Class III Devices

On February 2, 2026, the FDA's Quality System Regulation (QSR) in 21 CFR Part 820 transitioned to the Quality Management System Regulation (QMSR). The QMSR incorporates ISO 13485:2016 by reference, replacing the FDA-specific QSR requirements with the internationally harmonized standard.

For Class III device manufacturers, the practical implications include:

• Risk management integration — ISO 13485 requires a risk-based approach to quality management. For Class III devices, this means the QMS must demonstrate how the risk management process (per ISO 14971) is integrated into every aspect of the quality system, from design controls through post-market surveillance.
• Design and development — While the QMSR aligns with ISO 13485 design and development requirements, the FDA's expectations for Class III devices remain rigorous. PMA applicants must still demonstrate compliance with design control requirements through the Design History File (DHF), and the preapproval inspection will evaluate design controls against ISO 13485 Clauses 7.3.1 through 7.3.10.
• Supplier management — ISO 13485 places greater emphasis on supplier qualification and monitoring than the previous QSR. For Class III devices with complex supply chains, this means more formal supplier evaluation, purchasing specifications, and incoming inspection or verification procedures.
• PMA submission content — The FDA issued draft guidance in October 2025 titled "Quality Management System Information for Certain Premarket Submission Reviews," which describes how QMS information should be presented in PMA applications under the new QMSR framework.

Practical tip: If you are preparing a PMA application for submission in 2026 or later, ensure your quality system documentation references ISO 13485:2016 rather than the legacy 21 CFR 820 framework. FDA inspectors conducting preapproval inspections will evaluate your QMS against the QMSR requirements.

The Total Product Life Cycle (TPLC) Approach

The FDA's Center for Devices and Radiological Health (CDRH) uses a Total Product Life Cycle (TPLC) approach to regulate medical devices — and this framework is particularly relevant for Class III devices because of their extensive post-approval obligations.

Under the TPLC approach, the FDA views device regulation not as a one-time premarket gate but as a continuous oversight process spanning from device conception through post-market surveillance, end-of-life, and even recall. In 2019, CDRH reorganized its structure to align with this philosophy, combining premarket and postmarket review teams so that the same staff who review the PMA application also monitor the device's post-market performance.

The TPLC Database — The FDA maintains a publicly accessible TPLC database (accessible at accessdata.fda.gov/scripts/cdrh/cfdocs/cfTPLC/tplc.cfm) that integrates data from multiple CDRH databases, including:

• Product Classification codes
• PMA approval records and supplements
• 510(k) clearance records
• MAUDE (Manufacturer and User Facility Device Experience) adverse event reports
• Recall records

For Class III device manufacturers, the TPLC database is a valuable competitive intelligence tool. By searching a product code, you can see every approved PMA for that device type, all supplements, all reported adverse events, and all recalls — providing a complete picture of the regulatory history and real-world performance of competing devices. This information can inform your clinical study design, risk analysis, and PMA submission strategy.

Why TPLC matters for PMA strategy: The FDA's TPLC orientation means that reviewers evaluating your PMA are simultaneously considering what post-market requirements should be imposed if the device is approved. They are thinking about long-term safety signals, not just the data in front of them. Acknowledging this in your PMA — by proactively addressing post-market surveillance plans, proposing robust post-approval study designs, and demonstrating that your quality system is built for continuous monitoring — can strengthen your application and demonstrate regulatory maturity.

Pre-Amendment Class III Devices and the 510(k) Exception

What Are Pre-Amendment Devices?

When the Medical Device Amendments of 1976 were enacted, devices that were already legally on the market were "grandfathered" into the classification system. These are called pre-amendment (or preamendment) devices. For Class III pre-amendment devices, Congress recognized that requiring immediate PMA submissions for all of them would be impractical. Instead, these devices were allowed to continue marketing through the 510(k) pathway until the FDA affirmatively called for PMAs.

At the time, over 170 Class III device types were marketed through the 510(k) pathway under this provision. The intent was that the FDA would eventually require PMA for all of them, but the process of calling for PMAs has taken decades.

Section 515(b) Orders — When FDA Calls for PMA

When the FDA determines that sufficient information exists to require PMA for a pre-amendment Class III device type, it issues a final order under Section 515(b) of the FD&C Act. This order:

1. Announces that PMA is now required for the device type
2. Sets a deadline for manufacturers to submit PMAs (typically 90 days after the effective date of the order)
3. Establishes that devices of this type may no longer be marketed through 510(k) after the deadline

Manufacturers who do not submit a PMA by the deadline must stop marketing their devices. Those who submit a PMA may continue marketing while the application is under review.

The 515 Program Initiative

The FDA launched the 515 Program Initiative to systematically address the backlog of pre-amendment Class III devices. Through this program, the FDA evaluates each pre-amendment Class III device type and takes one of three actions:

• Call for PMA — The device remains Class III and PMA is now required
• Reclassify to Class II — The FDA determines that special controls (rather than PMA) are sufficient, and reclassifies the device to Class II with a 510(k) pathway
• Reclassify to Class I — Rare, but possible for devices whose risk profile is determined to be low

Many device types that were originally classified as Class III have been reclassified to Class II through this process. However, some pre-amendment Class III device types still exist on the 510(k) pathway because the FDA has not yet completed its review.

What Happens When a 515(b) Order Affects Your Device

If the FDA issues a 515(b) order calling for PMA for your device type, the practical implications are significant:

1. Review the effective date carefully. The order specifies when PMA is required. You typically have 90 days after the effective date to submit a PMA application.

2. You may continue marketing during PMA review. If you submit a PMA application by the deadline, you can continue to market your device while the FDA reviews it. This is a critical grace period — without a timely PMA submission, you must stop marketing.

3. Clinical data will be needed. The transition from 510(k) to PMA means you now need clinical evidence of safety and effectiveness, not just substantial equivalence. If you do not already have clinical data, you may need to conduct a clinical trial under an IDE, which takes years.

4. The business impact can be severe. For companies that have been marketing through 510(k) for decades, the sudden requirement for clinical trials, PMA user fees, and ongoing post-approval obligations represents a fundamental change in the cost structure of the product. Some manufacturers choose to exit the market rather than invest in PMA.

5. Reclassification may be an alternative. If you believe your device type does not warrant Class III classification, you can petition the FDA for reclassification to Class II under Section 513(e). This requires demonstrating that special controls are sufficient to assure safety and effectiveness. Some manufacturers have successfully used this strategy to avoid the PMA requirement.

Recent 515(b) Activity

The FDA continues to issue 515(b) orders as part of its ongoing effort to resolve the pre-amendment backlog. A notable recent example is the March 2026 Federal Register notice establishing an effective date for the PMA requirement for blood irradiators intended to prevent transfusion-associated graft-versus-host disease — a device type that had been marketed through 510(k) for decades.

Manufacturers of any pre-amendment Class III device should monitor the FDA's 515 Program Initiative page and subscribe to Federal Register alerts for their device type.

Practical tip: If you are marketing a Class III device through 510(k) under the pre-amendment exception, do not assume this will last forever. Monitor FDA Federal Register notices and the 515 Program Initiative page for orders affecting your device type. When a 515(b) order is issued, you will have a limited window to submit a PMA — and the clinical data requirements will be substantial.

Humanitarian Device Exemption (HDE)

What Is an HDE?

The Humanitarian Device Exemption (HDE) is an alternative pathway for Class III devices intended to treat or diagnose conditions that affect no more than 8,000 individuals in the United States per year. The HDE pathway is defined in 21 CFR Part 814, Subpart H.

The HDE was created to address a market failure: for very rare conditions, the small patient population makes it economically impractical to conduct the large clinical trials typically required for PMA. Without the HDE pathway, many devices for rare conditions would never be developed.

How HDE Differs from PMA

Requirement	PMA	HDE
Evidentiary standard	Reasonable assurance of safety and effectiveness	Safety (reasonable assurance) + probable benefit (not effectiveness)
Clinical data	Pivotal clinical trial data usually required	Clinical data for safety; no requirement for effectiveness data from a well-controlled trial
Annual distribution limit	None	No more than 8,000 devices per year
Profit restrictions	None	Profit permitted for HDE devices approved for pediatric use or after 2012 for adult use under certain conditions
IRB approval required for use?	No (once PMA is approved, any physician can use it)	Yes — each use requires IRB approval at the treating institution (unless FDA has granted an exemption)
User fee	$579,272 (standard)	Significantly reduced; small business waivers available

The Two-Step HDE Process

Step 1 — Humanitarian Use Device (HUD) Designation. Before submitting an HDE application, the manufacturer must obtain a HUD designation from the FDA's Office of Orphan Products Development (OOPD). This requires demonstrating that the device is intended for a condition affecting fewer than 8,000 patients per year in the US.

Step 2 — HDE Application. Once HUD designation is granted, the manufacturer submits an HDE application to the appropriate FDA premarket review center (usually CDRH). The application is similar in structure to a PMA but with the lower evidentiary bar of "probable benefit" rather than proven effectiveness.

HDE Examples and Real-World Applications

HDE-approved devices cover a wide range of rare conditions:

• Responsive neurostimulation systems for medically refractory epilepsy in patients who are not candidates for epilepsy surgery
• Implantable total artificial hearts as destination therapy for patients who are not transplant candidates
• Specialized pediatric cardiac devices where the small patient population makes full-scale clinical trials impractical
• Radiofrequency ablation systems for rare tumor types

HDE Post-Approval Obligations

Like PMA-approved devices, HDE devices are subject to post-approval requirements:

• Annual distribution reports showing compliance with the 8,000-device-per-year cap
• Post-approval studies if required as a condition of HDE approval
• Medical device reporting (21 CFR Part 803) for adverse events
• Periodic re-evaluation of the HUD designation to confirm the condition still affects fewer than 8,000 individuals per year

Converting from HDE to PMA

Some manufacturers initially enter the market through HDE and later transition to full PMA as more clinical data becomes available and the commercial opportunity grows. This transition requires conducting a clinical trial that meets PMA evidentiary standards and submitting a new PMA application. The advantage of this approach is that HDE approval provides early market access and generates real-world evidence that can inform the design of the pivotal PMA trial.

Practical tip: The HDE pathway is genuinely useful for rare-condition devices, but it comes with ongoing restrictions. The IRB approval requirement for each use can create logistical challenges for commercialization, and the distribution cap limits revenue potential. Consider whether a full PMA with a smaller, well-designed clinical trial might be feasible — it eliminates the post-approval restrictions.

PMA vs. 510(k) vs. De Novo: Choosing the Right Pathway

Understanding how PMA compares to the other FDA premarket pathways is essential for making the right strategic decision early in development.

Factor	PMA	510(k)	De Novo
Device class	Class III	Class I (non-exempt), Class II	Novel Class I or II (no predicate)
Standard of review	Reasonable assurance of safety and effectiveness	Substantial equivalence to a predicate	Reasonable assurance of safety and effectiveness
Predicate required?	No	Yes	No (device becomes the predicate for future 510(k)s)
Clinical data	Almost always required (pivotal trial)	Sometimes (depends on device)	Often required
Typical review time	12-18 months (calendar)	3-5 months (calendar)	5-8 months (calendar)
User fee (FY2026, standard)	$579,272	$26,067	$173,782
User fee (FY2026, small business)	$144,818	$6,517	$43,446
Post-market changes	PMA supplement required	New 510(k) or letter-to-file	New 510(k) or letter-to-file
Annual reporting	Yes (PMA annual report)	No	No
Post-approval studies	Frequently required	Rarely	Rarely
Total cost to market	$30M-$100M+ (including clinical trials)	$50K-$500K	$200K-$2M

When You Cannot Avoid PMA

PMA is required when:

• Your device is classified as Class III and a PMA regulation exists for your device type
• Your device is novel (no predicate, no existing classification) and the risk profile is too high for De Novo classification into Class I or II
• The FDA has issued a 515(b) order requiring PMA for your pre-amendment Class III device type
• Your device is a combination product where the device component drives the overall risk to Class III level

When You Might Not Need PMA Despite Class III Classification

• Pre-amendment Class III devices where the FDA has not yet called for PMA — these can still use 510(k)
• Devices reclassified from Class III to Class II through the 515 Program Initiative or a reclassification petition
• HDE-eligible devices — still Class III, but the HDE pathway has a lower evidentiary standard

FY2026 User Fees for PMA and Related Submissions

The FDA's medical device user fees are set annually under the Medical Device User Fee Amendments (MDUFA). For fiscal year 2026 (October 1, 2025 through September 30, 2026), the fees for PMA-related submissions are:

Submission Type	Standard Fee	Small Business Fee
PMA application	$579,272	$144,818
Panel-Track PMA supplement	$289,636	$72,409
180-Day PMA supplement	$173,782	$43,446
Real-Time PMA supplement	$26,067	$6,517
Annual establishment registration	$9,760	$9,760

Small Business Qualification

To qualify for reduced small business fees, a company must have gross receipts or sales of no more than $100 million for the most recent tax year. Companies with gross receipts of no more than $30 million may also qualify for a first-PMA fee waiver — meaning the user fee for their first PMA, PDP, or BLA is waived entirely.

Small business qualification requires submitting a Small Business Determination (SBD) request to the FDA. The qualification applies for one fiscal year and must be renewed annually.

Practical tip: The user fee is a small fraction of total PMA costs, but it is due at submission — before you know whether the FDA will accept your application. If your application is refused at the RTA stage, you may be eligible for a partial refund, but the process takes time. Make sure your application is complete before submitting.

Timeline and True Cost of PMA

Realistic Timeline

The total time from initial concept to PMA approval for a Class III medical device is typically 7 to 12 years. Here is how that time breaks down:

Phase	Typical Duration
Preclinical development (design, prototyping, bench testing, animal studies)	2-4 years
Pre-Submission meeting and IDE application	3-6 months
IDE review by FDA	30 days (significant risk)
Pivotal clinical trial (enrollment + follow-up)	2-5 years
PMA preparation and submission	6-12 months
FDA review (including deficiency responses)	12-18 months
Manufacturing scale-up and launch	6-12 months
Total concept to market	7-12+ years

Why Timelines Extend Beyond Estimates

Several factors commonly cause PMA timelines to extend beyond initial projections:

• Clinical trial enrollment delays — Recruiting patients for pivotal trials of high-risk devices is challenging. Strict inclusion/exclusion criteria, patient reluctance to participate in studies of implantable devices, and competition from other clinical trials can slow enrollment significantly. Many pivotal trials take 50-100% longer to enroll than originally projected.
• Clinical hold or IDE modification — The FDA may place a clinical hold on an IDE study if safety concerns arise during the trial, or may require protocol amendments that reset enrollment or add additional endpoints.
• Multiple deficiency rounds — While the FDA targets a 180-day review clock, clock stops for deficiency responses can extend the calendar time considerably. Complex devices may receive three or more Major Deficiency letters, each requiring weeks or months of response preparation.
• Advisory panel scheduling — If the FDA decides to convene an advisory panel for your device, the panel meeting must be scheduled on the FDA calendar. Panel meetings are public events that require significant preparation, and scheduling delays of 3-6 months are common.
• Manufacturing readiness gaps — Preapproval inspection findings can delay the final approval decision until the manufacturer addresses quality system deficiencies. If the FDA issues a Warning Letter based on the preapproval inspection, approval is effectively blocked until the issues are resolved.

True Cost

Published estimates of the total cost to bring a Class III medical device through PMA range from $30 million to over $100 million. A 2022 study published in JAMA estimated the median cost of developing a therapeutic complex medical device at approximately $94 million. The major cost drivers are:

• Clinical trials: 40-60% of the total budget. Pivotal trials for Class III devices can cost $10 million to $50 million or more, depending on the number of patients, number of sites, length of follow-up, and complexity of the device
• Preclinical testing: 10-20% — bench testing, biocompatibility (ISO 10993), animal studies, software verification and validation, electromagnetic compatibility
• Regulatory activities: 10-15% — regulatory strategy, submission preparation, FDA interactions, user fees
• Manufacturing development: 15-25% — design transfer, process validation, quality system establishment, facility build-out
• Commercialization: 5-10% — labeling, physician training, reimbursement strategy

Combination Products Classified as Class III

A combination product is a product that combines a medical device with a drug, biologic, or both. Many combination products are classified as Class III because the device component poses significant risk. Examples include:

• Drug-eluting coronary stents — A stent (device) coated with a drug that prevents restenosis. The device component is the primary mode of action, so the product is regulated by the Center for Devices and Radiological Health (CDRH) with input from the Center for Drug Evaluation and Research (CDER)
• Antimicrobial wound dressings with drug components — Wound dressing (device) incorporating a drug for infection prevention
• Pre-filled drug delivery devices — Auto-injectors or implantable pumps pre-filled with specific drug products
• Tissue-engineered products — Scaffolds (device) combined with cells or growth factors (biologic)

The regulatory pathway for combination products depends on the primary mode of action (PMOA). If the device component provides the PMOA, the combination product is regulated as a device — and if it is high-risk, it follows the PMA pathway. If the drug or biologic component provides the PMOA, the product is regulated under an NDA (drug) or BLA (biologic), with the device component addressed through a device-specific section.

Combination products must comply with 21 CFR Part 4, which requires compliance with both device requirements (QMSR) and drug/biologic requirements (current Good Manufacturing Practice under 21 CFR Parts 210/211), unless the FDA grants an exemption.

Regulatory Complexity of Combination Products

The PMA process for device-led combination products is notably more complex than for device-only products because:

• Dual expertise required — The review team includes both device and drug/biologic reviewers. The drug component is evaluated for pharmacokinetics, toxicology, stability, and compatibility with the device, in addition to the standard device safety and effectiveness review.
• Drug-device interaction studies — The manufacturer must demonstrate that the drug and device components function properly together, including elution kinetics (for drug-eluting devices), drug stability within the device, and any effects of the device on drug bioavailability.
• Manufacturing complexity — Combination product manufacturing must comply with both device GMP (QMSR/ISO 13485) and drug GMP (21 CFR 210/211) requirements, often requiring dual-track quality systems or formal exemptions.
• Labeling requirements — Combination product labeling must address both the device component (per 21 CFR 801) and the drug component (per 21 CFR 201), including drug-specific information such as dosage, pharmacology, and drug interactions.
• Post-market reporting — Adverse events involving combination products may need to be reported under both the MDR regulation (21 CFR 803) and the drug adverse event reporting regulation (21 CFR 314.80 or 21 CFR 600.80), depending on which component is implicated.

Practical tip: If your device incorporates any drug, biologic, or human tissue component, request a designation from the FDA's Office of Combination Products (OCP) early — ideally before beginning preclinical testing. The designation determines which FDA center has primary jurisdiction and which regulatory pathway applies. Getting this wrong can result in a complete restart of your regulatory strategy.

AI/ML-Enabled Devices at the Class III Level

The vast majority of FDA-authorized AI/ML-enabled medical devices have been cleared through the 510(k) pathway as Class II devices. Out of the approximately 950+ AI/ML devices authorized by the FDA as of early 2026, fewer than five have been approved through PMA as Class III devices.

It is important to distinguish between AI/ML-enabled medical devices and Software as a Medical Device (SaMD) more broadly. The International Medical Device Regulators Forum (IMDRF) developed a risk-based classification framework for SaMD that assigns categories 1 through 4 based on the seriousness of the healthcare condition and the significance of the software's contribution to clinical decision-making. IMDRF Category IV SaMD — software that drives treatment decisions for critical conditions — aligns most closely with FDA Class III. The FDA has incorporated elements of the IMDRF framework into its own SaMD approach, though the FDA's classification system (Class I/II/III) and the IMDRF SaMD categories are not directly interchangeable.

The regulatory landscape for AI/ML devices is evolving. Devices that use AI/ML algorithms for high-risk diagnostic or therapeutic decisions — particularly those where an incorrect output could directly cause death or serious injury — may be classified as Class III. Examples include:

• AI-based cardiac diagnostic software that identifies life-threatening arrhythmias without physician oversight
• Autonomous surgical planning systems that make treatment decisions for high-risk procedures
• AI-driven closed-loop therapy devices (e.g., autonomous insulin delivery systems with advanced predictive algorithms)

Predetermined Change Control Plans (PCCPs)

In August 2025, the FDA finalized guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled devices. A PCCP allows manufacturers to pre-specify types of modifications they plan to make to their AI/ML algorithms after marketing, including retraining with new data. If the FDA approves the PCCP as part of the original marketing submission, the manufacturer can implement the specified changes without submitting a new marketing application.

For Class III AI/ML devices, PCCPs are included in the PMA application and any changes outside the approved PCCP scope require a PMA supplement.

The Regulatory Challenge for High-Risk AI/ML

The fundamental tension for AI/ML devices at the Class III level is between the FDA's traditional PMA model — which evaluates a fixed, locked-down device — and the nature of AI/ML algorithms, which improve through continuous learning and retraining. A PMA approval covers a specific version of the algorithm, and any modification that could affect safety or effectiveness requires a PMA supplement. Without a PCCP, even routine algorithm retraining could trigger a supplement requirement, creating a regulatory bottleneck that discourages innovation.

The PCCP framework attempts to resolve this by allowing manufacturers to pre-specify a "modification protocol" — describing the types of changes they plan to make, the data they will use, the validation methods they will employ, and the performance guardrails that must be met. If FDA approves the PCCP, the manufacturer can implement changes within its scope without a new submission. For Class III AI/ML devices, the PCCP must be included in the original PMA and is reviewed with the same rigor as any other section of the application.

This regulatory framework is still maturing. As more AI/ML devices target Class III indications — particularly in autonomous diagnostics and closed-loop therapy — expect additional FDA guidance and potentially new regulatory pathways tailored to adaptive algorithms.

International Comparison: FDA Class III vs. Global Equivalents

Class III is an FDA-specific classification. Other major regulatory markets use different classification systems, and a device classified as Class III by the FDA may not receive the equivalent highest-risk classification elsewhere (and vice versa).

Jurisdiction	Equivalent to FDA Class III	Highest Risk Class	Approval Body	Key Pathway
EU (MDR)	Class III (and certain Class IIb implantables)	Class III	Notified Body (with scrutiny procedure involving expert panels)	CE Marking via conformity assessment
Japan (PMDA)	Class IV (highest risk)	Class IV	PMDA (Pharmaceuticals and Medical Devices Agency)	Shonin (marketing approval)
Canada (Health Canada)	Class IV	Class IV	Health Canada	Medical Device Licence
Australia (TGA)	Class III / AIMD	Class III / AIMD	Therapeutic Goods Administration	ARTG inclusion
China (NMPA)	Class III	Class III	National Medical Products Administration	Registration certificate
Brazil (ANVISA)	Class IV	Class IV	ANVISA	Product registration

Key Differences Between FDA PMA and EU MDR Class III

Aspect	FDA PMA	EU MDR Class III
Reviewer	FDA (government agency)	Notified Body (private, accredited organization) with European Commission scrutiny procedure
Evidentiary standard	Reasonable assurance of safety and effectiveness	Conformity with General Safety and Performance Requirements (Annex I)
Clinical evidence	Pivotal clinical trial data (usually RCTs)	Clinical evaluation based on clinical investigation data and/or literature review and equivalence claims
Post-market	Annual reports, post-approval studies	PMCF (Post-Market Clinical Follow-up), PSURs, PMS Plan
Timeline	12-18 months (FDA review)	Variable — depends on Notified Body capacity
Unique Device Identification	UDI required (21 CFR Part 830)	UDI required (EUDAMED)

EU MDR Scrutiny Procedure for Class III

One area where the EU MDR has moved closer to FDA-level rigor is the scrutiny procedure for Class III devices and certain Class IIb implantable devices. Under MDR Article 54, the Notified Body must submit its clinical evaluation assessment to an expert panel before issuing a CE certificate for high-risk devices. The expert panel (organized through the Medical Device Coordination Group) reviews the clinical evidence and may issue a scientific opinion recommending additional clinical data or conditions.

This scrutiny procedure did not exist under the prior Medical Device Directive (MDD) and represents a significant increase in regulatory oversight for high-risk devices in the EU. For companies planning dual US/EU submissions, the scrutiny procedure adds time and complexity to the EU pathway that must be factored into the global regulatory timeline.

Practical Implications for Global Manufacturers

Manufacturers planning to market a Class III device globally should consider these strategic points:

• Start clinical trials with both FDA and EU MDR requirements in mind. Design your pivotal study to generate data that satisfies both PMA and EU MDR clinical evaluation requirements. This may mean larger sample sizes, additional endpoints, or specific subgroup analyses that one jurisdiction requires but the other does not.
• Align quality systems to ISO 13485 from the start. With the QMSR transition, both the FDA and EU MDR now rely on ISO 13485 as the quality system standard. A single ISO 13485-compliant quality system can satisfy both jurisdictions, reducing duplication.
• Budget for jurisdiction-specific documentation. Even with shared clinical data, the FDA PMA and EU MDR Technical Documentation have different formats, required sections, and emphasis areas. You will need separate regulatory teams or consultants for each submission.
• Monitor regulatory timelines in both jurisdictions. FDA PMA timelines are more predictable than EU MDR Notified Body timelines, which vary significantly based on Notified Body capacity and the scrutiny procedure.

Practical tip: Do not assume that your PMA clinical data will satisfy EU MDR requirements, or vice versa. The EU MDR requires a Clinical Evaluation Report (CER) and Post-Market Clinical Follow-up (PMCF) plan, which have different structures and emphases than the PMA Summary of Safety and Effectiveness Data (SSED). Plan for both regulatory systems from the outset if you intend to market globally.

Reimbursement Considerations for Class III Devices

PMA approval grants marketing authorization, but it does not guarantee reimbursement. For most Class III devices — particularly implantable devices used in hospital settings — commercial success depends on securing adequate reimbursement from Medicare, Medicaid, and private payers.

Medicare Coverage

For novel Class III devices, Medicare coverage typically requires:

• A CMS National Coverage Determination (NCD) or Local Coverage Determination (LCD) establishing that the device is "reasonable and necessary" for the treatment of a condition
• Assignment of appropriate coding — CPT (Current Procedural Terminology) codes for the procedure and ICD-10 codes for the diagnosis
• Adequate payment rates — For hospital outpatient settings, devices are paid under the Outpatient Prospective Payment System (OPPS) via Ambulatory Payment Classifications (APCs). For inpatient settings, payment is typically bundled into the DRG (Diagnosis-Related Group) rate, though high-cost devices may qualify for a New Technology Add-on Payment (NTAP)

New Technology Add-on Payments (NTAP)

CMS may grant an NTAP for medical technologies that meet three criteria:

1. Newness — The technology must be new (within 2-3 years of commercial availability)
2. Cost — The cost of the technology must substantially exceed the current DRG payment for the applicable diagnosis
3. Clinical improvement — The technology must represent a substantial clinical improvement over existing treatments

For Class III devices with PMA approval, the NTAP can provide additional Medicare payment above the DRG rate for up to 2-3 years, giving the device time to establish a clinical track record and achieve broader adoption.

Parallel Review Program

The FDA and CMS offer a Parallel Review program that allows simultaneous FDA PMA review and CMS National Coverage Determination (NCD) review for certain devices. This can accelerate the time from PMA approval to Medicare coverage, which historically has been a significant barrier to commercial adoption of innovative Class III devices.

Practical tip: Begin your reimbursement strategy during device development, not after PMA approval. Identify the relevant CPT and DRG codes, estimate the expected hospital costs, and engage health economics consultants to develop a value dossier that supports coverage and payment. A PMA-approved device without adequate reimbursement will struggle commercially regardless of its clinical benefits.

Common PMA Deficiencies and How to Avoid Them

The FDA refuses to accept or issues deficiency letters for PMA applications with disturbing frequency. Understanding the most common problems can save months or years.

Refuse to Accept (RTA) Issues

These are threshold problems that prevent the FDA from even beginning its substantive review:

1. Missing sections — The application does not contain all required elements under 21 CFR 814.20. Common omissions include environmental assessments, complete labeling, or financial disclosure forms
2. Incorrect user fee — Fee not paid, wrong amount, or payment not linked to the submission
3. Inadequate device description — The device is not described in sufficient detail for FDA reviewers to understand how it works
4. Missing or incomplete clinical data — Clinical study reports that reference data not included in the submission

Substantive Review Deficiencies

These are issues identified during the FDA's in-depth review:

1. Insufficient statistical power — The clinical study was not adequately powered to detect a clinically meaningful difference in the primary endpoint
2. Protocol deviations — Significant deviations from the approved IDE study protocol that compromise the integrity of the results
3. Incomplete adverse event reporting — All adverse events must be captured, analyzed, and attributed (device-related, procedure-related, or unrelated)
4. Biocompatibility gaps — Missing ISO 10993 testing for materials in contact with patients, particularly for novel materials
5. Software documentation deficiencies — For software-driven devices, inadequate software hazard analysis, incomplete verification and validation, or missing cybersecurity documentation
6. Manufacturing process validation gaps — Insufficient evidence that the manufacturing process consistently produces devices that meet specifications
7. Labeling deficiencies — Warnings, contraindications, or instructions for use that do not adequately reflect the clinical data and risk profile
8. Sterilization validation issues — For sterile devices, incomplete sterilization validation or inadequate demonstration of sterility assurance level (SAL)

How to Minimize Deficiencies

• Use the Pre-Submission process — Get FDA feedback on your clinical study design, endpoints, and analytical methods before conducting the pivotal trial
• Follow the RTA checklist — The FDA publishes an Acceptance Checklist for PMA applications. Use it as your quality control before submitting
• Conduct a mock audit of your quality system before submission — FDA will inspect your manufacturing facility as part of the PMA review
• Engage experienced regulatory counsel — PMA submissions are too complex and consequential for first-time submitters to navigate alone
• Reference FDA guidance documents — Device-specific guidance documents often specify exactly what bench testing, clinical data, and labeling the FDA expects for your device type
• Conduct a completeness review against 21 CFR 814.20 — Go through each required section systematically and verify that all referenced documents, data tables, and appendices are actually included in the submission
• Resolve all open CAPAs before submission — Outstanding corrective and preventive actions will be identified during the preapproval inspection and may delay approval
• Prepare a clean SSED — The Summary of Safety and Effectiveness Data is the public-facing document that FDA publishes upon approval. Errors, inconsistencies, or unclear writing in the SSED create extra work for reviewers and signal carelessness

Cybersecurity Requirements for Class III Devices

For Class III devices that contain software, connect to networks, or have wireless capabilities, cybersecurity is now a formal component of the PMA submission. The FDA's February 2026 final guidance, "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions," establishes clear expectations.

What Must Be Included in the PMA

• Threat model — A systematic analysis of potential cybersecurity threats to the device, including unauthorized access, data manipulation, denial of service, and exploitation of software vulnerabilities
• Cybersecurity risk assessment — An assessment of the likelihood and impact of each identified threat, integrated with the device's overall risk management process (per ISO 14971)
• Security architecture — Description of the device's security controls, including authentication, encryption, access control, audit logging, software update mechanisms, and data integrity protections
• Software bill of materials (SBOM) — A complete list of all software components, including third-party libraries and open-source components, with version numbers. This is now mandatory under Section 524B of the FD&C Act
• Vulnerability management plan — A plan for identifying, assessing, and remediating cybersecurity vulnerabilities throughout the device's lifecycle, including coordinated vulnerability disclosure procedures
• Security testing results — Results of penetration testing, fuzz testing, and other security validation activities

Impact on Class III Devices Specifically

The cybersecurity requirements are particularly consequential for Class III devices because:

• Many Class III devices are implantable and cannot be easily updated after deployment (e.g., pacemakers, neurostimulators)
• Network-connected Class III devices used in hospital environments (e.g., ventilators, ECMO systems) are potential targets for ransomware attacks
• A cybersecurity compromise in a life-sustaining device could directly result in patient death

Practical tip: Integrate cybersecurity into your device design from the earliest stages — it is not something you can bolt on before submission. The FDA expects cybersecurity to be part of the design control process, not a last-minute afterthought. For Class III devices, budget for professional penetration testing and consider engaging a cybersecurity firm with medical device experience.

Regulatory Strategy for Startups Facing Class III

For startup companies developing Class III devices, the regulatory pathway presents unique challenges that differ fundamentally from the Class II/510(k) experience that many first-time founders expect.

Funding Implications

The PMA timeline (7-12+ years) and cost ($30M-$100M+) mean that Class III devices require significantly more capital than Class II devices. Most Class III device companies need multiple rounds of venture capital or strategic investment to reach PMA approval. The funding milestones for a Class III startup typically align with regulatory milestones:

• Seed / Series A — Concept validation, initial prototyping, pre-clinical feasibility data, Pre-Sub meeting with FDA
• Series B — Design freeze, GLP animal studies, biocompatibility testing, IDE submission, manufacturing process development
• Series C / D — Clinical trial execution, enrollment completion, follow-up data maturation
• Pre-IPO / Series E — PMA submission, FDA review, preapproval inspection, manufacturing scale-up
• Post-approval — Commercial launch, post-approval studies, market development, reimbursement establishment

Investors evaluating Class III device companies will scrutinize the regulatory strategy closely. Having a clear pathway to PMA, FDA Pre-Sub meeting minutes showing alignment on study design, and a realistic clinical trial enrollment plan are critical for fundraising.

De Novo as a Class III Alternative

Before committing to the PMA pathway, startup companies should rigorously evaluate whether their device truly requires Class III classification. Many novel devices default to Class III under Section 513(f) simply because no existing classification exists — not because their risk profile genuinely warrants the highest level of control.

The De Novo pathway allows a manufacturer to request classification into Class I or Class II by demonstrating that general controls (Class I) or general plus special controls (Class II) are sufficient. A successful De Novo:

• Avoids the full PMA burden (user fee of $173,782 vs. $579,272; no mandatory post-approval studies)
• Creates a new classification regulation and product code
• Establishes the device as a predicate for future 510(k) submissions by competitors — which is a strategic advantage if you are first to market
• Typically requires clinical data, but often less extensive than a PMA pivotal trial

The decision between PMA and De Novo should be made early — ideally before the Pre-Sub meeting — because it affects clinical study design, regulatory strategy, timeline, and funding requirements.

Building a PMA-Ready Quality System

For startups, building a quality system that can withstand an FDA preapproval inspection is a significant undertaking. Common mistakes include:

• Delaying quality system implementation until close to PMA submission. The FDA expects to see design controls applied throughout development — retroactively documenting design activities does not meet the requirement.
• Underinvesting in CAPA and complaint handling procedures. Even pre-commercial companies should have robust CAPA systems in place, as these are among the first areas inspected during preapproval inspections.
• Insufficient document control. Every design decision, test result, risk analysis, and manufacturing specification must be controlled, versioned, and retrievable. The preapproval inspector will ask for specific documents and expect them to be produced quickly.
• Ignoring supplier controls. For Class III devices, the FDA expects formal qualification of all critical component suppliers, purchasing specifications, and incoming inspection procedures.

Practical tip: For a startup targeting Class III, hire or contract an experienced regulatory affairs professional and quality system manager within the first year of operation — not after the device is designed. The cost of rebuilding a quality system to meet FDA expectations is far greater than the cost of building it correctly from the start.

The PMA Lifecycle at a Glance

The following table provides a complete view of the PMA lifecycle — from initial concept through ongoing post-market obligations. This is not a one-time submission; it is a continuous regulatory relationship.

Phase	Activities	Typical Duration	Key Regulations
1. Classification & Strategy	Confirm Class III classification, identify regulatory pathway, assess De Novo eligibility, evaluate Breakthrough Designation	1-3 months	21 CFR 860, Section 513 FD&C Act
2. Pre-Submission	Prepare and submit Pre-Sub (Q-Sub), meet with FDA, align on study design, endpoints, and regulatory expectations	3-6 months	FDA Pre-Sub Guidance
3. Preclinical Development	Design controls, bench testing, biocompatibility (ISO 10993), animal studies, software V&V, sterilization validation, EMC testing	2-4 years	21 CFR 820 / QMSR, ISO 14971, ISO 10993, IEC 62304
4. IDE Application	Prepare and submit IDE, obtain IRB approval at clinical sites, receive FDA IDE approval	3-6 months	21 CFR 812
5. Clinical Trial	Conduct pivotal study, enroll patients, collect safety and effectiveness data, manage adverse events, close out sites	2-5 years	21 CFR 812, 50, 54, 56; ICH GCP
6. PMA Preparation	Compile application (device description, non-clinical data, clinical data, manufacturing info, labeling, SSED), submit with user fee	6-12 months	21 CFR 814.20
7. FDA Review	RTA screening, filing review, substantive review, deficiency responses, advisory panel (if applicable), preapproval inspection	12-18 months	21 CFR 814 Subpart B and C
8. Approval & Launch	Receive approval letter, complete manufacturing scale-up, launch commercially, submit UDI data	3-6 months	21 CFR 814.80, 830
9. Post-Approval	Annual reports, PMA supplements for changes, post-approval studies, MDR compliance, device tracking, CAPA maintenance	Ongoing (life of device)	21 CFR 814.82, 814.84, 803, 821

Key Takeaways

• Class III is the highest-risk FDA device classification, reserved for devices that sustain life, are implanted, or present a potential unreasonable risk of illness or injury. Only about 10% of device types are Class III.

• PMA is the required pathway for most Class III devices. It demands valid scientific evidence — typically from well-controlled clinical trials — demonstrating that the device is safe and effective. This is a fundamentally higher bar than the 510(k) substantial equivalence standard.

• PMA is expensive and time-consuming. Total development costs range from $30 million to over $100 million, with timelines of 7 to 12 years from concept to market. The FY2026 PMA user fee alone is $579,272 (standard) or $144,818 (small business).

• Clinical trials require an IDE. You cannot legally conduct a significant-risk clinical trial of a Class III device without an approved Investigational Device Exemption.

• Post-approval obligations are extensive. Annual reports, post-approval studies, medical device reporting, device tracking, and PMA supplements for changes are all conditions of continued approval.

• Pre-amendment Class III devices are a shrinking exception. Some Class III devices can still use 510(k), but the FDA's 515 Program Initiative is systematically closing this pathway through reclassification or PMA calls.

• The HDE pathway exists for rare conditions (affecting fewer than 8,000 patients per year) but comes with ongoing restrictions including IRB approval for each use and distribution caps.

• Use the Pre-Submission process. Early alignment with FDA on clinical study design, endpoints, and regulatory strategy is the single most effective way to reduce risk of delays and deficiency letters.

• Plan globally from the start. FDA PMA data does not automatically satisfy EU MDR or other international requirements. Build a global regulatory strategy during device development, not after US approval.

• Consider the Modular PMA for long development timelines. If your clinical trial will take years, a Modular PMA lets you submit and have FDA review completed sections (preclinical, manufacturing) while the trial is ongoing, reducing the post-submission review timeline.

• Know the four PMA submission methods. Traditional PMA, Modular PMA, Product Development Protocol (PDP), and Humanitarian Device Exemption (HDE) each serve different development stages and device types. Choosing the right method is a strategic decision that affects timeline and cost.

Frequently Asked Questions

What is the difference between Class II and Class III medical devices?

Class II devices are moderate-risk devices subject to general controls and special controls. They typically reach the US market through 510(k) clearance by demonstrating substantial equivalence to a predicate device. Class III devices are high-risk devices for which general and special controls are insufficient — they require Premarket Approval (PMA), which demands affirmative evidence of safety and effectiveness, usually from clinical trials. The evidentiary standard, cost, timeline, and ongoing regulatory obligations are all significantly higher for Class III.

How long does it take to get PMA approval?

The FDA's statutory review period is 180 days, but the actual calendar time from submission to approval is typically 12 to 18 months due to clock stops for deficiency responses. The total time from initial concept to PMA approval is usually 7 to 12 years, including preclinical development, IDE submission, clinical trials, and FDA review.

How much does a PMA cost?

The FY2026 FDA user fee for a PMA application is $579,272 (standard) or $144,818 (small business). However, the user fee is a tiny fraction of the total cost. Including clinical trials, preclinical testing, regulatory preparation, and manufacturing development, total costs to bring a Class III device through PMA typically range from $30 million to over $100 million.

Can a Class III device go through 510(k) instead of PMA?

In limited circumstances, yes. Pre-amendment Class III devices — those on the market before the Medical Device Amendments of 1976 — can still be marketed through 510(k) if the FDA has not issued a 515(b) order calling for PMA for that device type. However, the number of Class III devices eligible for 510(k) is shrinking as the FDA works through the backlog under its 515 Program Initiative.

What is the difference between PMA and 510(k)?

A 510(k) requires demonstrating that your device is substantially equivalent to a legally marketed predicate device. A PMA requires demonstrating, through valid scientific evidence, that your device is safe and effective for its intended use — no predicate is needed. PMA involves a more rigorous review, almost always requires clinical trial data, costs significantly more (user fee of $579,272 vs. $26,067), and imposes ongoing post-approval obligations including annual reports and PMA supplements for changes.

What happens if my PMA is denied?

If the FDA issues a "Not Approvable" letter, it will describe the deficiencies and may identify what additional data or changes are needed. You can address the deficiencies and resubmit, or request a hearing. A denial does not permanently prevent you from marketing the device — it means the current application is insufficient. Many ultimately successful PMAs received Not Approvable letters before final approval, though the remediation process can add years and significant expense.

What clinical trials are required for PMA?

PMA almost always requires clinical data from one or more pivotal studies conducted under an approved Investigational Device Exemption (IDE). Randomized controlled trials are the gold standard, but the FDA accepts other designs (single-arm studies with performance goals, historically controlled studies, Bayesian adaptive designs) when appropriate. The specific requirements — sample size, endpoints, follow-up duration, control groups — depend on the device type and should be aligned with FDA through the Pre-Submission process.

Do I need a PMA supplement for every change to my device?

Not every change requires a supplement. Changes that affect safety or effectiveness require a PMA supplement (type depends on the magnitude of the change — panel-track, 180-day, real-time, or 135-day). Manufacturing process changes may qualify for a 30-day notice. Minor changes that do not affect safety or effectiveness can be documented internally and reported in the annual report. When in doubt, consult 21 CFR 814.39 and the FDA guidance on PMA supplements.

What is a Humanitarian Device Exemption?

An HDE is an alternative pathway for Class III devices intended to treat or diagnose conditions affecting no more than 8,000 individuals per year in the US. The evidentiary standard is lower than PMA — the manufacturer must show safety and "probable benefit" rather than proven effectiveness. However, HDE devices are subject to ongoing restrictions including IRB approval requirements for each use and distribution limitations.

How are AI/ML devices classified as Class III?

Most FDA-authorized AI/ML devices are Class II (cleared through 510(k)). An AI/ML device may be classified as Class III if its algorithm makes autonomous diagnostic or therapeutic decisions where errors could directly cause death or serious injury, and where general and special controls are insufficient to mitigate the risk. Fewer than five AI/ML devices had been approved through PMA as of early 2026. The FDA's 2025 guidance on Predetermined Change Control Plans (PCCPs) provides a framework for managing AI/ML algorithm updates post-approval.

What post-approval obligations come with PMA?

PMA holders must submit annual reports (21 CFR 814.84), comply with medical device reporting requirements (21 CFR Part 803), maintain device tracking systems for applicable devices (21 CFR Part 821), submit PMA supplements for any changes that affect safety or effectiveness, conduct post-approval studies if required as a condition of approval, and maintain full compliance with the Quality Management System Regulation (QMSR). Failure to meet these obligations can result in withdrawal of approval.

Can I transfer a PMA to another company?

Yes. PMA ownership can be transferred through a PMA supplement. This commonly occurs when a company acquires another company's product line, when a device business is sold, or when a company restructures. The transfer supplement must include the new owner's establishment registration, quality system information, and confirmation that the new owner will assume all post-approval responsibilities. The FDA reviews transfer supplements as 180-day supplements.

What is the Breakthrough Device Designation and how does it help Class III devices?

The Breakthrough Device Designation is a program that provides priority review, enhanced FDA engagement, and collaborative review for devices that represent breakthrough technologies or offer significant advantages over existing treatments for life-threatening or irreversibly debilitating conditions. For Class III devices, the designation can accelerate the PMA timeline through more interactive review, involvement of senior FDA management, and exploration of efficient clinical study designs such as Bayesian adaptive trials or surrogate endpoints. The designation does not change the evidentiary standard — the FDA still requires reasonable assurance of safety and effectiveness.

What is a Modular PMA and when should I use it?

A Modular PMA allows you to submit individual sections (modules) of your PMA application to the FDA as they are completed, rather than waiting until the entire application is ready. The FDA reviews each module as it is received. This approach is best suited for devices in the early or middle stages of clinical investigation, where preclinical and manufacturing data are complete but clinical data collection is still ongoing. The key advantage is that by the time you submit the final clinical data module, the FDA has already reviewed and cleared the earlier sections, reducing the time from final submission to decision. However, Modular PMA is not appropriate if your device design is still changing or if you are close to completing your clinical study.

What is the FDA's Total Product Life Cycle (TPLC) approach?

The FDA's TPLC approach views device regulation as continuous oversight from device conception through post-market surveillance and end-of-life — not just a one-time premarket review. CDRH reorganized in 2019 to combine premarket and postmarket review teams, so the same staff who review your PMA also monitor the device's post-market performance. The FDA maintains a public TPLC database that integrates product classification data, PMA approvals, 510(k) clearances, MAUDE adverse event reports, and recall records — a useful research tool for understanding the regulatory history of your device type.

How does the QMSR transition affect Class III device manufacturers?

The transition from the Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR), effective February 2, 2026, incorporates ISO 13485:2016 by reference into the FDA's quality system requirements. For Class III manufacturers, this means updating quality system documentation to reference ISO 13485, ensuring risk management is integrated throughout the QMS per ISO 14971, and meeting enhanced supplier management requirements. PMA applications submitted after the transition should present QMS information aligned with the QMSR framework. FDA preapproval inspections will evaluate compliance against ISO 13485 requirements rather than the legacy QSR.